A carregar...
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the most commonly mutated genes in cancer(1,2). The majority of ARID1A mutations are inactivating mutations and lead to loss of ARID1A expression(3), which makes ARID1A a poor therapeutic target. Therefore, it is of clinical...
Na minha lista:
| Publicado no: | Nat Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6076433/ https://ncbi.nlm.nih.gov/pubmed/29736026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-018-0012-z |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|